TRACON Pharmaceuticals, Inc. (TCON) financial statements (2021 and earlier)

Company profile

Business Address 4350 LA JOLLA VILLAGE DRIVE
SAN DIEGO, CA 92122
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:361639354452
Cash and cash equivalents321625293641
Short-term investments4 145911
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)(0)0(0)0
Other undisclosed current assets112211
Total current assets:371741364653
Noncurrent Assets
Property, plant and equipment000000
Other noncurrent assets     0
Other undisclosed noncurrent assets11    
Total noncurrent assets:110000
TOTAL ASSETS:371841364654
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities211121
Employee-related liabilities211121
Debt631301
Deferred revenue and credits113
Other undisclosed current liabilities3811778
Total current liabilities:111213121014
Noncurrent Liabilities
Long-term debt and lease obligation135577
Long-term debt, excluding current maturities135577
Liabilities, other than long-term debt010301
Deferred revenue and credits2  
Accounts payable and accrued liabilities     1
Other liabilities01000 
Total noncurrent liabilities:246778
Total liabilities:121519191723
Stockholders' equity
Stockholders' equity attributable to parent25321172831
Common stock000000
Additional paid in capital20416516112211490
Accumulated deficit(179)(162)(140)(105)(86)(59)
Total stockholders' equity:25321172831
TOTAL LIABILITIES AND EQUITY:371841364654

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net938
Gross profit:  3938
Operating expenses(16)(22)(38)(27)(29)(31)
Operating loss:(16)(22)(35)(18)(26)(23)
Nonoperating expense(1)(0)(0)(1)(1)(1)
Net loss attributable to parent:(17)(23)(35)(19)(27)(24)
Preferred stock dividends and other adjustments     (0)
Net loss available to common stockholders, diluted:(17)(23)(35)(19)(27)(24)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(17)(23)(35)(19)(27)(24)
Comprehensive loss, net of tax, attributable to parent:(17)(23)(35)(19)(27)(24)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: